| 國立成功大學 |
2022 |
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na�ve Patients with�EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
|
Tu, H.-Y.;Feng, J.;Shi, M.;Zhao, J.;Wang, Y.;Chang, J.;Wang, J.;Cheng, Y.;Zhu, J.;Tan, E.-H.;Li, K.;Zhang, Y.;Lee, V.;Yang, C.-T.;Su, W.-C.;Lam, D.C.-L.;Srinivasa, B.J.;Rajappa, S.;Ho, C.-L.;Lam, K.C.;Hu, Y.;Bondarde, S.A.;Liu, X.;Tian, Y.;Xue, Z.;Cseh, A.;Huang, D.C.-L.;Zhou, C.;Wu, Y.-L. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
|
Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. |
| 中山醫學大學 |
2021 |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
|
Chang, GC; Lam, DCL; Tsai, CM; Chen, YM; Shih, JY; Aggarwal, S; Wang, SH; Kim, SW; Kim, YC; Wahid, I; Li, RB; Lim, DWT; Sriuranpong, V; Chan, RTT; Lorence, RM; Carriere, P; Raabe, C; Cseh, A; Park, K |
| 臺大學術典藏 |
2020-08-13T06:33:29Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.; Gautschi O.; Liao W.-Y.; Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Jin-Yuan Shih;Liao W.-Y.;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-13T06:33:29Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.; Gautschi O.; Liao W.-Y.; Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Jin-Yuan Shih;Liao W.-Y.;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C. |
| 臺大學術典藏 |
2018 |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Shih J.-Y.;Wei-Yu Liao;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; Shih J.-Y.; WEI-YU LIAO; Gautschi O.; Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C. |
| 臺大學術典藏 |
2018 |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Shih J.-Y.;Wei-Yu Liao;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; Shih J.-Y.; WEI-YU LIAO; Gautschi O.; Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C. |
